Trial Outcomes & Findings for A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (NCT NCT05019521)

NCT ID: NCT05019521

Last Updated: 2025-09-05

Results Overview

FAF provides high-contrast retinal images particularly valuable for the detection of atrophic areas. FAF images of the study eye were taken and sent to the reading center for total GA lesion area measurement. The total GA lesion area (square millimeter \[mm\^2\]) was transformed into sqrt (millimeter \[mm\]). Greater area affected means a worse outcome than smaller area affected. The rate of change from Baseline (mm/year) for each treatment group was estimated based on the coefficients for time and the interaction of time and treatment from the mixed models for repeated measures (MMRM). MMRM analysis included the change from Baseline at post-baseline visit in the sqrt GA lesion area as dependent variable.

• Recruitment status: TERMINATED
• Study phase: PHASE2
• Target enrollment: 365 participants
• Primary outcome timeframe: Baseline, Week 52
• Results posted on: 2025-09-05

Participant Flow

The study included 104-week Masked Treatment Period (Masked Placebo-controlled [Primary Evaluation Period; up to 52 weeks] and Masked Active Treatment [Secondary Evaluation Period; Week 52 to Week 104]). As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.

For standardization purposes, the primary and secondary efficacy analyses were measured in the pre-specified study eye per individual participant. In this study, ocular assessments were performed in both eyes at Screening. The eye that met all eligibility criteria was designated as the study eye and the other eye was used as the fellow eye. If both eyes were eligible, the right eye was designated as the study eye.

Participant milestones

Measure	Danicopan 100 mg BID Participants received danicopan 100 milligrams (mg) twice daily (BID) during the 104-week Masked Treatment Period.	Danicopan 200 mg BID Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD Participants received danicopan 400 mg once daily (QD) during the 104-week Masked Treatment Period.	Placebo Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Primary Evaluation Period (52 Weeks) STARTED	93	91	91	90	0	0	0
Primary Evaluation Period (52 Weeks) Received at Least 1 Dose of Study Drug	93	91	91	90	0	0	0
Primary Evaluation Period (52 Weeks) COMPLETED	73	67	73	70	0	0	0
Primary Evaluation Period (52 Weeks) NOT COMPLETED	20	24	18	20	0	0	0
Secondary Evaluation Period (52 Weeks) STARTED	73	67	73	0	24	23	23
Secondary Evaluation Period (52 Weeks) Received at Least 1 Dose of Study Drug	73	67	73	0	24	23	23
Secondary Evaluation Period (52 Weeks) COMPLETED	15	14	11	0	5	2	3
Secondary Evaluation Period (52 Weeks) NOT COMPLETED	58	53	62	0	19	21	20

Reasons for withdrawal

Measure	Danicopan 100 mg BID Participants received danicopan 100 milligrams (mg) twice daily (BID) during the 104-week Masked Treatment Period.	Danicopan 200 mg BID Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD Participants received danicopan 400 mg once daily (QD) during the 104-week Masked Treatment Period.	Placebo Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Primary Evaluation Period (52 Weeks) Adverse Event	7	9	8	4	0	0	0
Primary Evaluation Period (52 Weeks) Investigator's Discretion	1	1	0	2	0	0	0
Primary Evaluation Period (52 Weeks) Withdrawal by Subject	7	13	6	9	0	0	0
Primary Evaluation Period (52 Weeks) Lost to Follow-up	1	0	1	0	0	0	0
Primary Evaluation Period (52 Weeks) Death	0	1	0	3	0	0	0
Primary Evaluation Period (52 Weeks) Liver abnormalities meeting Hy's Law criteria	1	0	0	0	0	0	0
Primary Evaluation Period (52 Weeks) Other Than Specified	3	0	3	2	0	0	0
Secondary Evaluation Period (52 Weeks) Adverse Event	2	3	2	0	0	0	3
Secondary Evaluation Period (52 Weeks) Investigator's Discretion	1	2	1	0	0	0	1
Secondary Evaluation Period (52 Weeks) Withdrawal by Subject	3	0	0	0	5	2	2
Secondary Evaluation Period (52 Weeks) Lack of Efficacy	0	1	2	0	0	0	0
Secondary Evaluation Period (52 Weeks) Death	0	1	1	0	1	0	0
Secondary Evaluation Period (52 Weeks) Liver abnormalities meeting Hy's Law criteria	0	0	0	0	0	1	0
Secondary Evaluation Period (52 Weeks) Other Than Specified	3	1	3	0	0	1	0
Secondary Evaluation Period (52 Weeks) Study Terminated by Sponsor	49	45	53	0	13	17	14

Baseline Characteristics

A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Baseline characteristics by cohort

Measure	Danicopan 100 mg BID n=93 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=91 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=91 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=90 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Total n=365 Participants Total of all reporting groups
Age, Continuous	77.0 years STANDARD_DEVIATION 7.20 • n=5 Participants	76.0 years STANDARD_DEVIATION 7.24 • n=7 Participants	77.8 years STANDARD_DEVIATION 7.52 • n=5 Participants	77.8 years STANDARD_DEVIATION 6.75 • n=4 Participants	77.1 years STANDARD_DEVIATION 7.19 • n=21 Participants
Sex: Female, Male Female	68 Participants n=5 Participants	58 Participants n=7 Participants	64 Participants n=5 Participants	61 Participants n=4 Participants	251 Participants n=21 Participants
Sex: Female, Male Male	25 Participants n=5 Participants	33 Participants n=7 Participants	27 Participants n=5 Participants	29 Participants n=4 Participants	114 Participants n=21 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	4 Participants n=5 Participants	1 Participants n=7 Participants	4 Participants n=5 Participants	6 Participants n=4 Participants	15 Participants n=21 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	75 Participants n=5 Participants	81 Participants n=7 Participants	77 Participants n=5 Participants	75 Participants n=4 Participants	308 Participants n=21 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	14 Participants n=5 Participants	9 Participants n=7 Participants	10 Participants n=5 Participants	9 Participants n=4 Participants	42 Participants n=21 Participants
Race/Ethnicity, Customized Race · Asian	2 Participants n=5 Participants	1 Participants n=7 Participants	3 Participants n=5 Participants	3 Participants n=4 Participants	9 Participants n=21 Participants
Race/Ethnicity, Customized Race · Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants
Race/Ethnicity, Customized Race · White	77 Participants n=5 Participants	81 Participants n=7 Participants	78 Participants n=5 Participants	76 Participants n=4 Participants	312 Participants n=21 Participants
Race/Ethnicity, Customized Race · Not Reported	11 Participants n=5 Participants	6 Participants n=7 Participants	6 Participants n=5 Participants	6 Participants n=4 Participants	29 Participants n=21 Participants
Race/Ethnicity, Customized Race · Unknown	3 Participants n=5 Participants	3 Participants n=7 Participants	4 Participants n=5 Participants	2 Participants n=4 Participants	12 Participants n=21 Participants
Race/Ethnicity, Customized Race · Other	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	2 Participants n=4 Participants	2 Participants n=21 Participants

PRIMARY outcome

Timeframe: Baseline, Week 52

Population: All participants in the FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment group) who had any post-baseline FAF GA lesion area data at the Week 52 analysis. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.

FAF provides high-contrast retinal images particularly valuable for the detection of atrophic areas. FAF images of the study eye were taken and sent to the reading center for total GA lesion area measurement. The total GA lesion area (square millimeter [mm^2]) was transformed into sqrt (millimeter [mm]). Greater area affected means a worse outcome than smaller area affected. The rate of change from Baseline (mm/year) for each treatment group was estimated based on the coefficients for time and the interaction of time and treatment from the mixed models for repeated measures (MMRM). MMRM analysis included the change from Baseline at post-baseline visit in the sqrt GA lesion area as dependent variable.

Outcome measures

Measure	Danicopan 100 mg BID n=65 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=62 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=70 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=66 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Rate of Change From Baseline to Week 52 in the Square Root (Sqrt) of Total Geographic Atrophy (GA) Lesion Area in the Study Eye as Measured by Fundus Autofluorescence (FAF)	0.465 mm/year Standard Error 0.0289	0.391 mm/year Standard Error 0.0306	0.443 mm/year Standard Error 0.0301	0.406 mm/year Standard Error 0.0304	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 104

Population: All participants in the FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment group) with both baseline visit and post-baseline (Week 104) visit FAF GA lesion area data. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.

FAF provides high-contrast retinal images particularly valuable for the detection of atrophic areas. FAF images of the study eye were taken and sent to the reading center for total GA lesion area measurement. The total GA lesion area (mm^2) was transformed into sqrt (mm). Greater area affected means a worse outcome than smaller area affected.

Outcome measures

Measure	Danicopan 100 mg BID n=18 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=13 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=18 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=6 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=4 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=4 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 104 in the Sqrt of the Total GA Lesion Area in the Study Eye as Measured by FAF	0.892 mm Standard Deviation 0.4545	0.705 mm Standard Deviation 0.3831	0.859 mm Standard Deviation 0.3468	0.668 mm Standard Deviation 0.4866	0.585 mm Standard Deviation 0.1396	0.787 mm Standard Deviation 0.1858	—	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in the FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment group) with both baseline and post-baseline (Week 52 and Week 104) visit FAF GA lesion area data. As prespecified, data were collected and reported for participants. Therefore, 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. Number analyzed = participants evaluable at specified timepoints.

FAF provides high-contrast retinal images particularly valuable for the detection of atrophic areas. FAF images of the study eye were taken and sent to the reading center for total GA lesion area (mm^2) measurement. Greater area affected means a worse outcome than smaller area affected.

Outcome measures

Measure	Danicopan 100 mg BID n=65 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=62 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=70 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=66 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=20 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=22 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 and Week 104 in the Total GA Lesion Area in the Study Eye as Measured by FAF Change at Week 52	2.347 mm^2 Standard Deviation 1.2972	2.044 mm^2 Standard Deviation 1.2280	2.274 mm^2 Standard Deviation 1.4482	2.057 mm^2 Standard Deviation 1.2016	1.887 mm^2 Standard Deviation 1.1212	1.716 mm^2 Standard Deviation 0.9095	2.553 mm^2 Standard Deviation 1.3938	—	—	—
Change From Baseline to Week 52 and Week 104 in the Total GA Lesion Area in the Study Eye as Measured by FAF Change at Week 104	4.311 mm^2 Standard Deviation 2.8803	3.223 mm^2 Standard Deviation 2.3784	4.504 mm^2 Standard Deviation 2.1300	—	3.309 mm^2 Standard Deviation 2.5878	3.653 mm^2 Standard Deviation 2.3125	5.098 mm^2 Standard Deviation 1.8250	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in the FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment group) with both baseline and post-baseline (Week 52 and Week 104) visit SD-OCT data. As prespecified, data were collected and reported for participants. Therefore, 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. Number analyzed = participants evaluable for specified categories.

Photoreceptor loss was assessed by measuring the percent of macular EZ total attenuation using SD-OCT. The EZ was considered to be formed mainly by mitochondria within the ellipsoid layer of the outer portion of the inner segments of the photoreceptors. In SD-OCT, decreases in the integrity and intensity of the EZ have been correlated with the reduction in cone photoreceptors and retinal sensitivity in retinal degenerative diseases. Lower increase in percentage means a better outcome. Higher increase in percentage means a worse outcome.

Outcome measures

Measure	Danicopan 100 mg BID n=72 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=65 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=72 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=70 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 and Week 104 in Percent Macular Ellipsoid Zone (EZ) Total Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by Spectral-domain Optical Coherence Tomography (SD-OCT) Study Eye: Change at Week 52	8.70 percentage of EZ total attenuation Standard Deviation 4.681	7.48 percentage of EZ total attenuation Standard Deviation 4.226	8.66 percentage of EZ total attenuation Standard Deviation 4.633	7.50 percentage of EZ total attenuation Standard Deviation 4.814	6.03 percentage of EZ total attenuation Standard Deviation 3.147	7.74 percentage of EZ total attenuation Standard Deviation 4.469	8.77 percentage of EZ total attenuation Standard Deviation 6.206	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Macular Ellipsoid Zone (EZ) Total Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by Spectral-domain Optical Coherence Tomography (SD-OCT) Study Eye: Change at Week 104	13.54 percentage of EZ total attenuation Standard Deviation 7.664	11.72 percentage of EZ total attenuation Standard Deviation 7.976	15.27 percentage of EZ total attenuation Standard Deviation 6.156	—	10.81 percentage of EZ total attenuation Standard Deviation 6.514	12.65 percentage of EZ total attenuation Standard Deviation 5.163	14.76 percentage of EZ total attenuation Standard Deviation 6.672	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Macular Ellipsoid Zone (EZ) Total Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by Spectral-domain Optical Coherence Tomography (SD-OCT) Fellow Eye: Change at Week 52	6.31 percentage of EZ total attenuation Standard Deviation 3.642	5.53 percentage of EZ total attenuation Standard Deviation 3.665	6.96 percentage of EZ total attenuation Standard Deviation 4.684	7.87 percentage of EZ total attenuation Standard Deviation 4.790	7.31 percentage of EZ total attenuation Standard Deviation 4.898	7.26 percentage of EZ total attenuation Standard Deviation 4.164	8.94 percentage of EZ total attenuation Standard Deviation 5.205	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Macular Ellipsoid Zone (EZ) Total Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by Spectral-domain Optical Coherence Tomography (SD-OCT) Fellow Eye: Change at Week 104	12.80 percentage of EZ total attenuation Standard Deviation 7.605	9.48 percentage of EZ total attenuation Standard Deviation 5.396	14.05 percentage of EZ total attenuation Standard Deviation 9.509	—	11.82 percentage of EZ total attenuation Standard Deviation 9.719	12.34 percentage of EZ total attenuation Standard Deviation 5.174	14.19 percentage of EZ total attenuation Standard Deviation 3.223	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Macular Ellipsoid Zone (EZ) Total Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by Spectral-domain Optical Coherence Tomography (SD-OCT) Both Eyes Combined: Change at Week 52	13.77 percentage of EZ total attenuation Standard Deviation 7.285	11.27 percentage of EZ total attenuation Standard Deviation 6.892	14.94 percentage of EZ total attenuation Standard Deviation 8.335	14.02 percentage of EZ total attenuation Standard Deviation 8.564	12.17 percentage of EZ total attenuation Standard Deviation 7.625	13.43 percentage of EZ total attenuation Standard Deviation 7.072	16.55 percentage of EZ total attenuation Standard Deviation 10.412	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Macular Ellipsoid Zone (EZ) Total Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by Spectral-domain Optical Coherence Tomography (SD-OCT) Both Eyes Combined: Change at Week 104	22.18 percentage of EZ total attenuation Standard Deviation 15.324	17.17 percentage of EZ total attenuation Standard Deviation 13.337	28.51 percentage of EZ total attenuation Standard Deviation 12.937	—	20.65 percentage of EZ total attenuation Standard Deviation 15.245	22.53 percentage of EZ total attenuation Standard Deviation 7.748	28.95 percentage of EZ total attenuation Standard Deviation 7.702	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in the FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment group) with both baseline and post-baseline (Week 52 and Week 104) visit SD-OCT data. As prespecified, data were collected and reported for participants. Therefore, 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. Number analyzed = participants evaluable for specified categories.

Photoreceptor degradation was assessed by measuring the percent of macular EZ partial attenuation using SD-OCT. The EZ was considered to be formed mainly by mitochondria within the ellipsoid layer of the outer portion of the inner segments of the photoreceptors. In SD-OCT, decreases in the integrity and intensity of the EZ have been correlated with the reduction in cone photoreceptors and retinal sensitivity in retinal degenerative diseases. Lower increase in percentage means a better outcome. Higher increase in percentage means a worse outcome.

Outcome measures

Measure	Danicopan 100 mg BID n=72 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=65 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=72 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=70 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 and Week 104 in Percent Macular EZ Partial Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 52	6.42 percentage of EZ partial attenuation Standard Deviation 4.917	5.15 percentage of EZ partial attenuation Standard Deviation 3.806	6.63 percentage of EZ partial attenuation Standard Deviation 4.599	5.65 percentage of EZ partial attenuation Standard Deviation 4.365	4.00 percentage of EZ partial attenuation Standard Deviation 3.423	5.54 percentage of EZ partial attenuation Standard Deviation 4.089	7.49 percentage of EZ partial attenuation Standard Deviation 4.946	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Macular EZ Partial Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 52	5.74 percentage of EZ partial attenuation Standard Deviation 4.531	4.28 percentage of EZ partial attenuation Standard Deviation 3.646	5.61 percentage of EZ partial attenuation Standard Deviation 4.987	6.31 percentage of EZ partial attenuation Standard Deviation 4.370	4.90 percentage of EZ partial attenuation Standard Deviation 3.399	5.83 percentage of EZ partial attenuation Standard Deviation 4.616	8.15 percentage of EZ partial attenuation Standard Deviation 4.563	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Macular EZ Partial Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 104	12.48 percentage of EZ partial attenuation Standard Deviation 7.290	8.06 percentage of EZ partial attenuation Standard Deviation 6.728	13.87 percentage of EZ partial attenuation Standard Deviation 7.495	—	7.75 percentage of EZ partial attenuation Standard Deviation 4.677	10.55 percentage of EZ partial attenuation Standard Deviation 7.536	10.56 percentage of EZ partial attenuation Standard Deviation 6.122	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Macular EZ Partial Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 104	11.09 percentage of EZ partial attenuation Standard Deviation 6.771	7.87 percentage of EZ partial attenuation Standard Deviation 5.927	13.79 percentage of EZ partial attenuation Standard Deviation 9.773	—	6.20 percentage of EZ partial attenuation Standard Deviation 6.897	11.52 percentage of EZ partial attenuation Standard Deviation 8.433	13.48 percentage of EZ partial attenuation Standard Deviation 3.926	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Macular EZ Partial Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 52	11.10 percentage of EZ partial attenuation Standard Deviation 8.110	8.10 percentage of EZ partial attenuation Standard Deviation 5.976	11.69 percentage of EZ partial attenuation Standard Deviation 8.277	10.90 percentage of EZ partial attenuation Standard Deviation 7.617	8.11 percentage of EZ partial attenuation Standard Deviation 5.784	10.10 percentage of EZ partial attenuation Standard Deviation 6.989	14.60 percentage of EZ partial attenuation Standard Deviation 8.644	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Macular EZ Partial Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 104	19.85 percentage of EZ partial attenuation Standard Deviation 14.357	12.67 percentage of EZ partial attenuation Standard Deviation 10.789	26.92 percentage of EZ partial attenuation Standard Deviation 14.542	—	12.92 percentage of EZ partial attenuation Standard Deviation 10.399	19.77 percentage of EZ partial attenuation Standard Deviation 11.361	24.04 percentage of EZ partial attenuation Standard Deviation 8.185	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment) with both baseline and post-baseline (Week 52 and Week 104) visit ONL-RPE mean central 1 mm subfield thickness data. As prespecified, data were collected and reported for participants. Hence, 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. Number analyzed = participants evaluable for specified categories.

The ONL - RPE mean central 1 mm subfield thickness refers to the average thickness of the retinal layers between the ONL and RPE measured within a 1 mm radius from the foveal center (the central point of the retina).

Outcome measures

Measure	Danicopan 100 mg BID n=72 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=65 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=72 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=70 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 and Week 104 in Outer Nuclear Layer (ONL) - Retinal Pigment Epithelium (RPE) Mean Central 1 mm Subfield Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 52	-4.60 micrometers (µm) Standard Deviation 13.366	-4.48 micrometers (µm) Standard Deviation 13.398	-4.86 micrometers (µm) Standard Deviation 13.345	-3.10 micrometers (µm) Standard Deviation 10.666	-0.51 micrometers (µm) Standard Deviation 10.404	-2.53 micrometers (µm) Standard Deviation 8.417	-6.41 micrometers (µm) Standard Deviation 12.496	—	—	—
Change From Baseline to Week 52 and Week 104 in Outer Nuclear Layer (ONL) - Retinal Pigment Epithelium (RPE) Mean Central 1 mm Subfield Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 104	-12.63 micrometers (µm) Standard Deviation 23.455	-10.01 micrometers (µm) Standard Deviation 29.953	-12.47 micrometers (µm) Standard Deviation 23.648	—	-22.77 micrometers (µm) Standard Deviation 38.733	-14.72 micrometers (µm) Standard Deviation 14.931	-12.76 micrometers (µm) Standard Deviation 15.206	—	—	—
Change From Baseline to Week 52 and Week 104 in Outer Nuclear Layer (ONL) - Retinal Pigment Epithelium (RPE) Mean Central 1 mm Subfield Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 52	-7.83 micrometers (µm) Standard Deviation 13.457	-4.65 micrometers (µm) Standard Deviation 12.206	-7.63 micrometers (µm) Standard Deviation 15.236	-7.63 micrometers (µm) Standard Deviation 15.088	-4.69 micrometers (µm) Standard Deviation 13.097	-9.01 micrometers (µm) Standard Deviation 17.029	-9.39 micrometers (µm) Standard Deviation 15.478	—	—	—
Change From Baseline to Week 52 and Week 104 in Outer Nuclear Layer (ONL) - Retinal Pigment Epithelium (RPE) Mean Central 1 mm Subfield Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 104	-13.84 micrometers (µm) Standard Deviation 25.155	-12.00 micrometers (µm) Standard Deviation 6.459	-16.53 micrometers (µm) Standard Deviation 25.363	—	-14.28 micrometers (µm) Standard Deviation 14.915	-26.53 micrometers (µm) Standard Deviation 10.412	-26.32 micrometers (µm) Standard Deviation 18.045	—	—	—
Change From Baseline to Week 52 and Week 104 in Outer Nuclear Layer (ONL) - Retinal Pigment Epithelium (RPE) Mean Central 1 mm Subfield Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 52	-11.16 micrometers (µm) Standard Deviation 16.448	-7.77 micrometers (µm) Standard Deviation 18.785	-11.75 micrometers (µm) Standard Deviation 21.771	-9.55 micrometers (µm) Standard Deviation 20.028	-4.60 micrometers (µm) Standard Deviation 19.446	-9.57 micrometers (µm) Standard Deviation 19.250	-14.70 micrometers (µm) Standard Deviation 20.919	—	—	—
Change From Baseline to Week 52 and Week 104 in Outer Nuclear Layer (ONL) - Retinal Pigment Epithelium (RPE) Mean Central 1 mm Subfield Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 104	-22.29 micrometers (µm) Standard Deviation 31.682	-17.78 micrometers (µm) Standard Deviation 28.793	-28.34 micrometers (µm) Standard Deviation 39.848	—	-34.67 micrometers (µm) Standard Deviation 50.039	-35.94 micrometers (µm) Standard Deviation 25.831	-39.08 micrometers (µm) Standard Deviation 32.217	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment) with both baseline and post-baseline (Week 52 and Week 104) visit ONL-RPE mean central macular 2 mm thickness data. As prespecified, data were collected and reported for participants. Therefore, 'Ns' reported below= number of participants analyzed regardless of which eye was evaluated. Number analyzed = participants evaluable for specified categories.

The ONL - RPE mean central macular 2 mm subfield thickness refers to the thickness of the retina in the central part of the macula, specifically within a 2 mm radius.

Outcome measures

Measure	Danicopan 100 mg BID n=72 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=65 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=72 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=70 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 and Week 104 in ONL-RPE Mean Central Macular 2 mm Subfield Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 52	-7.42 µm Standard Deviation 7.354	-6.56 µm Standard Deviation 9.960	-8.04 µm Standard Deviation 8.589	-7.25 µm Standard Deviation 7.219	-4.85 µm Standard Deviation 6.749	-7.53 µm Standard Deviation 6.631	-9.46 µm Standard Deviation 7.805	—	—	—
Change From Baseline to Week 52 and Week 104 in ONL-RPE Mean Central Macular 2 mm Subfield Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 104	-17.49 µm Standard Deviation 14.707	-12.09 µm Standard Deviation 21.562	-15.47 µm Standard Deviation 11.523	—	-21.03 µm Standard Deviation 23.221	-14.62 µm Standard Deviation 6.409	-19.46 µm Standard Deviation 11.807	—	—	—
Change From Baseline to Week 52 and Week 104 in ONL-RPE Mean Central Macular 2 mm Subfield Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 52	-8.39 µm Standard Deviation 8.989	-5.91 µm Standard Deviation 9.783	-9.01 µm Standard Deviation 8.981	-7.92 µm Standard Deviation 9.205	-7.28 µm Standard Deviation 7.784	-7.04 µm Standard Deviation 7.522	-9.32 µm Standard Deviation 11.750	—	—	—
Change From Baseline to Week 52 and Week 104 in ONL-RPE Mean Central Macular 2 mm Subfield Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 104	-14.66 µm Standard Deviation 14.939	-14.86 µm Standard Deviation 11.321	-17.60 µm Standard Deviation 10.975	—	-13.48 µm Standard Deviation 10.615	-16.20 µm Standard Deviation 4.746	-20.98 µm Standard Deviation 12.521	—	—	—
Change From Baseline to Week 52 and Week 104 in ONL-RPE Mean Central Macular 2 mm Subfield Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 52	-14.33 µm Standard Deviation 11.799	-10.74 µm Standard Deviation 14.465	-16.18 µm Standard Deviation 13.333	-13.83 µm Standard Deviation 12.378	-11.01 µm Standard Deviation 11.299	-13.05 µm Standard Deviation 9.983	-17.56 µm Standard Deviation 14.952	—	—	—
Change From Baseline to Week 52 and Week 104 in ONL-RPE Mean Central Macular 2 mm Subfield Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 104	-27.07 µm Standard Deviation 19.859	-21.71 µm Standard Deviation 24.931	-32.26 µm Standard Deviation 19.723	—	-32.27 µm Standard Deviation 31.178	-27.58 µm Standard Deviation 13.280	-40.44 µm Standard Deviation 23.788	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in the FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment group) with both baseline and post-baseline (Week 52 and Week 104) visit EZ-RPE macular volume data. As prespecified, data were collected and reported for participants. Therefore, 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. Number analyzed = participants evaluable for specified categories.

The EZ - RPE macular volume refers to the volume of the retinal tissue between the EZ and the RPE, specifically within the macular region. Changes in EZ-RPE volume indicate the presence or progression of diseases affecting the outer retina.

Outcome measures

Measure	Danicopan 100 mg BID n=72 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=65 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=72 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=70 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 and Week 104 in Ellipsoid Zone (EZ) - (RPE) Macular Volume in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 52	-0.09 cubic millimeters (mm^3) Standard Deviation 0.074	-0.07 cubic millimeters (mm^3) Standard Deviation 0.047	-0.09 cubic millimeters (mm^3) Standard Deviation 0.048	-0.06 cubic millimeters (mm^3) Standard Deviation 0.063	-0.05 cubic millimeters (mm^3) Standard Deviation 0.063	-0.06 cubic millimeters (mm^3) Standard Deviation 0.058	-0.08 cubic millimeters (mm^3) Standard Deviation 0.069	—	—	—
Change From Baseline to Week 52 and Week 104 in Ellipsoid Zone (EZ) - (RPE) Macular Volume in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 104	-0.18 cubic millimeters (mm^3) Standard Deviation 0.066	-0.10 cubic millimeters (mm^3) Standard Deviation 0.098	-0.16 cubic millimeters (mm^3) Standard Deviation 0.089	—	-0.10 cubic millimeters (mm^3) Standard Deviation 0.064	-0.13 cubic millimeters (mm^3) Standard Deviation 0.107	-0.12 cubic millimeters (mm^3) Standard Deviation 0.068	—	—	—
Change From Baseline to Week 52 and Week 104 in Ellipsoid Zone (EZ) - (RPE) Macular Volume in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 52	-0.08 cubic millimeters (mm^3) Standard Deviation 0.062	-0.05 cubic millimeters (mm^3) Standard Deviation 0.047	-0.08 cubic millimeters (mm^3) Standard Deviation 0.059	-0.07 cubic millimeters (mm^3) Standard Deviation 0.052	-0.06 cubic millimeters (mm^3) Standard Deviation 0.052	-0.08 cubic millimeters (mm^3) Standard Deviation 0.052	-0.08 cubic millimeters (mm^3) Standard Deviation 0.053	—	—	—
Change From Baseline to Week 52 and Week 104 in Ellipsoid Zone (EZ) - (RPE) Macular Volume in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 104	-0.16 cubic millimeters (mm^3) Standard Deviation 0.097	-0.11 cubic millimeters (mm^3) Standard Deviation 0.056	-0.16 cubic millimeters (mm^3) Standard Deviation 0.122	—	-0.10 cubic millimeters (mm^3) Standard Deviation 0.082	-0.13 cubic millimeters (mm^3) Standard Deviation 0.075	-0.16 cubic millimeters (mm^3) Standard Deviation 0.037	—	—	—
Change From Baseline to Week 52 and Week 104 in Ellipsoid Zone (EZ) - (RPE) Macular Volume in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 52	-0.15 cubic millimeters (mm^3) Standard Deviation 0.115	-0.10 cubic millimeters (mm^3) Standard Deviation 0.069	-0.16 cubic millimeters (mm^3) Standard Deviation 0.089	-0.13 cubic millimeters (mm^3) Standard Deviation 0.098	-0.11 cubic millimeters (mm^3) Standard Deviation 0.103	-0.12 cubic millimeters (mm^3) Standard Deviation 0.082	-0.15 cubic millimeters (mm^3) Standard Deviation 0.106	—	—	—
Change From Baseline to Week 52 and Week 104 in Ellipsoid Zone (EZ) - (RPE) Macular Volume in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 104	-0.29 cubic millimeters (mm^3) Standard Deviation 0.170	-0.17 cubic millimeters (mm^3) Standard Deviation 0.143	-0.32 cubic millimeters (mm^3) Standard Deviation 0.174	—	-0.18 cubic millimeters (mm^3) Standard Deviation 0.135	-0.23 cubic millimeters (mm^3) Standard Deviation 0.133	-0.28 cubic millimeters (mm^3) Standard Deviation 0.069	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment) with both baseline and post-baseline (Week 52 and Week 104) visit EZ-RPE mean central 1 mm subfield thickness data. As prespecified, data were collected and reported for participants. Therefore, 'Ns' reported below= number of participants analyzed regardless of which eye was evaluated. Number analyzed = participants evaluable for specified categories.

The EZ - RPE mean central 1 mm subfield thickness is a measurement of the thickness of the ellipsoid zone, a layer within the retina, in the central 1 mm region. Changes in EZ-RPE thickness indicate damage or dysfunction within the photoreceptors, which is associated with various eye diseases like AMD.

Outcome measures

Measure	Danicopan 100 mg BID n=72 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=65 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=72 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=70 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 and Week 104 in EZ-RPE Mean Central 1 mm Subfield Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 52	-4.03 µm Standard Deviation 3.888	-3.48 µm Standard Deviation 4.243	-3.83 µm Standard Deviation 4.044	-3.16 µm Standard Deviation 4.466	-2.40 µm Standard Deviation 2.863	-3.85 µm Standard Deviation 6.048	-3.25 µm Standard Deviation 3.944	—	—	—
Change From Baseline to Week 52 and Week 104 in EZ-RPE Mean Central 1 mm Subfield Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 104	-8.32 µm Standard Deviation 4.050	-5.70 µm Standard Deviation 5.327	-6.47 µm Standard Deviation 5.111	—	-5.82 µm Standard Deviation 4.866	-6.76 µm Standard Deviation 6.100	-2.76 µm Standard Deviation 2.737	—	—	—
Change From Baseline to Week 52 and Week 104 in EZ-RPE Mean Central 1 mm Subfield Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 52	-2.51 µm Standard Deviation 4.076	-1.93 µm Standard Deviation 3.043	-3.01 µm Standard Deviation 3.685	-3.52 µm Standard Deviation 4.738	-3.51 µm Standard Deviation 4.338	-3.42 µm Standard Deviation 4.103	-3.61 µm Standard Deviation 5.753	—	—	—
Change From Baseline to Week 52 and Week 104 in EZ-RPE Mean Central 1 mm Subfield Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 104	-5.23 µm Standard Deviation 4.879	-4.26 µm Standard Deviation 3.160	-5.05 µm Standard Deviation 4.629	—	-4.10 µm Standard Deviation 7.591	-3.15 µm Standard Deviation 3.755	-4.30 µm Standard Deviation 5.902	—	—	—
Change From Baseline to Week 52 and Week 104 in EZ-RPE Mean Central 1 mm Subfield Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 52	-6.03 µm Standard Deviation 6.163	-4.85 µm Standard Deviation 5.035	-6.55 µm Standard Deviation 5.942	-6.09 µm Standard Deviation 6.692	-5.37 µm Standard Deviation 5.864	-6.53 µm Standard Deviation 7.175	-6.40 µm Standard Deviation 7.224	—	—	—
Change From Baseline to Week 52 and Week 104 in EZ-RPE Mean Central 1 mm Subfield Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 104	-11.41 µm Standard Deviation 8.175	-8.46 µm Standard Deviation 5.799	-11.18 µm Standard Deviation 7.506	—	-9.23 µm Standard Deviation 9.970	-9.28 µm Standard Deviation 7.248	-7.06 µm Standard Deviation 7.138	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment) with both baseline and post-baseline (Week 52 and Week 104) visit EZ-RPE mean central macular 2 mm thickness data. As prespecified, data were collected and reported for participants. Therefore, 'Ns' reported below= number of participants analyzed regardless of which eye was evaluated. Number analyzed = participants evaluable for specified categories.

The EZ - RPE mean central macular 2 mm thickness measurement reflects the distance between the outer border of the EZ and the inner border of the RPE layer, typically within a central 2 mm area. Decreased EZ-RPE thickness is an early indicator of disease, such as in dry AMD, where a thinning or loss of the EZ is a hallmark. Changes in EZ-RPE thickness is used to monitor treatment response in conditions like AMD.

Outcome measures

Measure	Danicopan 100 mg BID n=72 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=65 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=72 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=70 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 and Week 104 in EZ-RPE Mean Central Macular 2 mm Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 52	-3.45 µm Standard Deviation 2.971	-2.75 µm Standard Deviation 2.633	-3.20 µm Standard Deviation 2.622	-2.58 µm Standard Deviation 2.819	-2.58 µm Standard Deviation 3.012	-2.70 µm Standard Deviation 3.011	-2.45 µm Standard Deviation 2.512	—	—	—
Change From Baseline to Week 52 and Week 104 in EZ-RPE Mean Central Macular 2 mm Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 104	-7.44 µm Standard Deviation 3.218	-5.21 µm Standard Deviation 4.657	-5.46 µm Standard Deviation 3.400	—	-5.05 µm Standard Deviation 4.337	-5.56 µm Standard Deviation 3.808	-3.00 µm Standard Deviation 1.925	—	—	—
Change From Baseline to Week 52 and Week 104 in EZ-RPE Mean Central Macular 2 mm Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 52	-2.51 µm Standard Deviation 3.042	-1.93 µm Standard Deviation 3.082	-2.76 µm Standard Deviation 3.147	-3.22 µm Standard Deviation 3.844	-3.50 µm Standard Deviation 3.502	-2.97 µm Standard Deviation 3.983	-3.16 µm Standard Deviation 4.206	—	—	—
Change From Baseline to Week 52 and Week 104 in EZ-RPE Mean Central Macular 2 mm Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 104	-5.58 µm Standard Deviation 5.229	-3.38 µm Standard Deviation 2.564	-4.89 µm Standard Deviation 5.228	—	-3.50 µm Standard Deviation 6.461	-4.05 µm Standard Deviation 5.544	-3.80 µm Standard Deviation 4.506	—	—	—
Change From Baseline to Week 52 and Week 104 in EZ-RPE Mean Central Macular 2 mm Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 52	-5.46 µm Standard Deviation 4.343	-4.11 µm Standard Deviation 3.792	-5.68 µm Standard Deviation 4.637	-5.27 µm Standard Deviation 5.408	-5.54 µm Standard Deviation 5.618	-5.03 µm Standard Deviation 5.235	-5.23 µm Standard Deviation 5.584	—	—	—
Change From Baseline to Week 52 and Week 104 in EZ-RPE Mean Central Macular 2 mm Thickness in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 104	-10.96 µm Standard Deviation 7.034	-7.40 µm Standard Deviation 5.216	-10.06 µm Standard Deviation 7.266	—	-7.97 µm Standard Deviation 8.308	-8.80 µm Standard Deviation 7.525	-6.80 µm Standard Deviation 5.094	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in the FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment group) with both baseline and post-baseline (Week 52 and Week 104) visit SD-OCT data. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. Number analyzed = participants evaluable for specified categories.

The percentage of total attenuation of the EZ in the central 1 mm subfield is reported.

Outcome measures

Measure	Danicopan 100 mg BID n=72 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=65 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=72 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=70 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 and Week 104 in Percent Central 1 mm Subfield EZ Total Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 52	16.73 percentage of EZ total attenuation Standard Deviation 16.914	15.93 percentage of EZ total attenuation Standard Deviation 21.716	18.68 percentage of EZ total attenuation Standard Deviation 20.417	13.69 percentage of EZ total attenuation Standard Deviation 16.939	11.07 percentage of EZ total attenuation Standard Deviation 13.674	12.68 percentage of EZ total attenuation Standard Deviation 18.176	17.48 percentage of EZ total attenuation Standard Deviation 18.703	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central 1 mm Subfield EZ Total Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 104	22.31 percentage of EZ total attenuation Standard Deviation 17.890	20.14 percentage of EZ total attenuation Standard Deviation 19.616	39.81 percentage of EZ total attenuation Standard Deviation 26.391	—	19.40 percentage of EZ total attenuation Standard Deviation 19.132	18.21 percentage of EZ total attenuation Standard Deviation 23.796	19.61 percentage of EZ total attenuation Standard Deviation 16.593	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central 1 mm Subfield EZ Total Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 52	9.16 percentage of EZ total attenuation Standard Deviation 12.800	8.33 percentage of EZ total attenuation Standard Deviation 16.198	12.68 percentage of EZ total attenuation Standard Deviation 16.131	13.44 percentage of EZ total attenuation Standard Deviation 17.791	13.33 percentage of EZ total attenuation Standard Deviation 23.449	12.33 percentage of EZ total attenuation Standard Deviation 10.834	14.51 percentage of EZ total attenuation Standard Deviation 16.785	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central 1 mm Subfield EZ Total Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 104	20.59 percentage of EZ total attenuation Standard Deviation 15.693	13.59 percentage of EZ total attenuation Standard Deviation 16.375	24.22 percentage of EZ total attenuation Standard Deviation 22.988	—	10.43 percentage of EZ total attenuation Standard Deviation 12.638	13.11 percentage of EZ total attenuation Standard Deviation 12.384	18.81 percentage of EZ total attenuation Standard Deviation 17.001	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central 1 mm Subfield EZ Total Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 52	23.92 percentage of EZ total attenuation Standard Deviation 21.961	21.82 percentage of EZ total attenuation Standard Deviation 27.888	30.13 percentage of EZ total attenuation Standard Deviation 26.472	24.82 percentage of EZ total attenuation Standard Deviation 24.477	22.27 percentage of EZ total attenuation Standard Deviation 27.116	22.33 percentage of EZ total attenuation Standard Deviation 20.562	29.97 percentage of EZ total attenuation Standard Deviation 25.421	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central 1 mm Subfield EZ Total Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 104	36.13 percentage of EZ total attenuation Standard Deviation 29.699	28.93 percentage of EZ total attenuation Standard Deviation 27.084	61.94 percentage of EZ total attenuation Standard Deviation 38.776	—	28.09 percentage of EZ total attenuation Standard Deviation 27.090	28.70 percentage of EZ total attenuation Standard Deviation 31.841	38.42 percentage of EZ total attenuation Standard Deviation 27.959	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in the FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment group) with both baseline and post-baseline (Week 52 and Week 104) visit SD-OCT data. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. Number analyzed = participants evaluable for specified categories.

The percentage of partial attenuation of the EZ in the central 1 mm subfield is reported.

Outcome measures

Measure	Danicopan 100 mg BID n=72 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=65 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=72 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=70 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 and Week 104 in Percent Central 1 mm Subfield EZ Partial Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 52	10.31 percentage of EZ partial attenuation Standard Deviation 13.668	8.24 percentage of EZ partial attenuation Standard Deviation 12.342	9.51 percentage of EZ partial attenuation Standard Deviation 14.020	8.67 percentage of EZ partial attenuation Standard Deviation 13.691	6.65 percentage of EZ partial attenuation Standard Deviation 7.932	11.42 percentage of EZ partial attenuation Standard Deviation 18.493	7.92 percentage of EZ partial attenuation Standard Deviation 12.672	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central 1 mm Subfield EZ Partial Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 104	24.56 percentage of EZ partial attenuation Standard Deviation 14.964	16.86 percentage of EZ partial attenuation Standard Deviation 18.793	12.57 percentage of EZ partial attenuation Standard Deviation 16.778	—	17.58 percentage of EZ partial attenuation Standard Deviation 20.152	22.86 percentage of EZ partial attenuation Standard Deviation 18.298	4.08 percentage of EZ partial attenuation Standard Deviation 5.899	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central 1 mm Subfield EZ Partial Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 52	6.80 percentage of EZ partial attenuation Standard Deviation 14.277	5.39 percentage of EZ partial attenuation Standard Deviation 9.926	7.26 percentage of EZ partial attenuation Standard Deviation 12.982	9.92 percentage of EZ partial attenuation Standard Deviation 16.529	9.62 percentage of EZ partial attenuation Standard Deviation 12.575	9.45 percentage of EZ partial attenuation Standard Deviation 13.614	10.61 percentage of EZ partial attenuation Standard Deviation 22.125	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central 1 mm Subfield EZ Partial Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 104	13.35 percentage of EZ partial attenuation Standard Deviation 18.080	9.25 percentage of EZ partial attenuation Standard Deviation 10.751	12.65 percentage of EZ partial attenuation Standard Deviation 15.581	—	14.87 percentage of EZ partial attenuation Standard Deviation 29.975	5.76 percentage of EZ partial attenuation Standard Deviation 11.374	10.38 percentage of EZ partial attenuation Standard Deviation 18.139	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central 1 mm Subfield EZ Partial Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 52	15.74 percentage of EZ partial attenuation Standard Deviation 20.909	12.06 percentage of EZ partial attenuation Standard Deviation 15.349	16.06 percentage of EZ partial attenuation Standard Deviation 20.365	16.93 percentage of EZ partial attenuation Standard Deviation 21.887	14.79 percentage of EZ partial attenuation Standard Deviation 17.280	18.81 percentage of EZ partial attenuation Standard Deviation 23.297	17.27 percentage of EZ partial attenuation Standard Deviation 25.273	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central 1 mm Subfield EZ Partial Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 104	31.92 percentage of EZ partial attenuation Standard Deviation 29.615	22.85 percentage of EZ partial attenuation Standard Deviation 20.419	24.56 percentage of EZ partial attenuation Standard Deviation 23.689	—	29.97 percentage of EZ partial attenuation Standard Deviation 39.643	27.47 percentage of EZ partial attenuation Standard Deviation 22.597	14.46 percentage of EZ partial attenuation Standard Deviation 17.962	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in the FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment group) with both baseline and post-baseline (Week 52 and Week 104) visit SD-OCT data. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. Number analyzed = participants evaluable for specified categories.

The percentage of total attenuation of the EZ in the central macular 2 mm subfield is reported.

Outcome measures

Measure	Danicopan 100 mg BID n=72 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=65 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=72 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=70 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 and Week 104 in Percent Central Macular 2 mm Subfield EZ Total Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 52	16.04 percentage of EZ total attenuation Standard Deviation 12.199	13.61 percentage of EZ total attenuation Standard Deviation 13.797	16.10 percentage of EZ total attenuation Standard Deviation 12.422	12.89 percentage of EZ total attenuation Standard Deviation 11.554	12.66 percentage of EZ total attenuation Standard Deviation 11.515	11.15 percentage of EZ total attenuation Standard Deviation 8.184	14.96 percentage of EZ total attenuation Standard Deviation 14.456	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central Macular 2 mm Subfield EZ Total Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 104	27.98 percentage of EZ total attenuation Standard Deviation 14.597	23.25 percentage of EZ total attenuation Standard Deviation 15.725	32.56 percentage of EZ total attenuation Standard Deviation 15.265	—	21.46 percentage of EZ total attenuation Standard Deviation 20.555	17.50 percentage of EZ total attenuation Standard Deviation 6.271	19.63 percentage of EZ total attenuation Standard Deviation 7.982	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central Macular 2 mm Subfield EZ Total Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 52	9.80 percentage of EZ total attenuation Standard Deviation 11.161	8.84 percentage of EZ total attenuation Standard Deviation 11.049	11.54 percentage of EZ total attenuation Standard Deviation 11.821	13.21 percentage of EZ total attenuation Standard Deviation 12.847	15.14 percentage of EZ total attenuation Standard Deviation 14.786	11.79 percentage of EZ total attenuation Standard Deviation 10.311	12.48 percentage of EZ total attenuation Standard Deviation 13.098	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central Macular 2 mm Subfield EZ Total Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 104	21.45 percentage of EZ total attenuation Standard Deviation 21.023	12.76 percentage of EZ total attenuation Standard Deviation 9.657	22.72 percentage of EZ total attenuation Standard Deviation 20.095	—	11.59 percentage of EZ total attenuation Standard Deviation 13.028	18.41 percentage of EZ total attenuation Standard Deviation 13.948	16.20 percentage of EZ total attenuation Standard Deviation 13.464	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central Macular 2 mm Subfield EZ Total Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 52	23.81 percentage of EZ total attenuation Standard Deviation 17.076	19.87 percentage of EZ total attenuation Standard Deviation 18.112	26.52 percentage of EZ total attenuation Standard Deviation 18.341	23.84 percentage of EZ total attenuation Standard Deviation 19.218	25.38 percentage of EZ total attenuation Standard Deviation 19.781	20.37 percentage of EZ total attenuation Standard Deviation 14.102	25.71 percentage of EZ total attenuation Standard Deviation 23.057	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central Macular 2 mm Subfield EZ Total Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 104	41.63 percentage of EZ total attenuation Standard Deviation 25.286	31.50 percentage of EZ total attenuation Standard Deviation 18.865	53.57 percentage of EZ total attenuation Standard Deviation 30.657	—	31.12 percentage of EZ total attenuation Standard Deviation 24.754	32.22 percentage of EZ total attenuation Standard Deviation 18.972	35.83 percentage of EZ total attenuation Standard Deviation 17.546	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in the FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment group) with both baseline and post-baseline (Week 52 and Week 104) visit SD-OCT data. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. Number analyzed = participants evaluable for specified categories.

The percentage of partial attenuation of the EZ in the central macular 2 mm subfield is reported.

Outcome measures

Measure	Danicopan 100 mg BID n=72 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=65 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=72 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=70 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 and Week 104 in Percent Central Macular 2 mm Subfield EZ Partial Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 52	8.24 percentage of EZ partial attenuation Standard Deviation 10.598	6.09 percentage of EZ partial attenuation Standard Deviation 7.169	7.54 percentage of EZ partial attenuation Standard Deviation 8.630	6.37 percentage of EZ partial attenuation Standard Deviation 8.079	6.67 percentage of EZ partial attenuation Standard Deviation 7.237	6.93 percentage of EZ partial attenuation Standard Deviation 9.374	5.46 percentage of EZ partial attenuation Standard Deviation 7.746	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central Macular 2 mm Subfield EZ Partial Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 104	18.70 percentage of EZ partial attenuation Standard Deviation 12.603	12.71 percentage of EZ partial attenuation Standard Deviation 13.460	10.96 percentage of EZ partial attenuation Standard Deviation 11.518	—	12.12 percentage of EZ partial attenuation Standard Deviation 11.782	17.09 percentage of EZ partial attenuation Standard Deviation 13.793	5.12 percentage of EZ partial attenuation Standard Deviation 5.509	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central Macular 2 mm Subfield EZ Partial Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 52	6.24 percentage of EZ partial attenuation Standard Deviation 9.738	5.12 percentage of EZ partial attenuation Standard Deviation 9.238	6.73 percentage of EZ partial attenuation Standard Deviation 11.225	9.07 percentage of EZ partial attenuation Standard Deviation 12.589	9.62 percentage of EZ partial attenuation Standard Deviation 10.501	8.30 percentage of EZ partial attenuation Standard Deviation 12.676	9.17 percentage of EZ partial attenuation Standard Deviation 14.826	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central Macular 2 mm Subfield EZ Partial Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 104	13.98 percentage of EZ partial attenuation Standard Deviation 14.829	7.71 percentage of EZ partial attenuation Standard Deviation 7.689	12.49 percentage of EZ partial attenuation Standard Deviation 18.409	—	12.14 percentage of EZ partial attenuation Standard Deviation 25.712	9.47 percentage of EZ partial attenuation Standard Deviation 17.096	9.30 percentage of EZ partial attenuation Standard Deviation 13.802	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central Macular 2 mm Subfield EZ Partial Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 52	13.27 percentage of EZ partial attenuation Standard Deviation 14.756	9.71 percentage of EZ partial attenuation Standard Deviation 10.869	13.61 percentage of EZ partial attenuation Standard Deviation 15.682	13.96 percentage of EZ partial attenuation Standard Deviation 16.418	14.82 percentage of EZ partial attenuation Standard Deviation 15.686	13.42 percentage of EZ partial attenuation Standard Deviation 16.367	13.59 percentage of EZ partial attenuation Standard Deviation 17.862	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central Macular 2 mm Subfield EZ Partial Attenuation in the Study Eye, the Fellow Eye, and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 104	27.52 percentage of EZ partial attenuation Standard Deviation 23.015	17.70 percentage of EZ partial attenuation Standard Deviation 15.710	22.87 percentage of EZ partial attenuation Standard Deviation 24.193	—	22.24 percentage of EZ partial attenuation Standard Deviation 31.056	24.67 percentage of EZ partial attenuation Standard Deviation 24.320	14.41 percentage of EZ partial attenuation Standard Deviation 14.806	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment) with both baseline and post-baseline (Week 52 and Week 104) visit sub-RPE central 1 mm subfield mean thickness data. As prespecified, data were collected and reported for participants. Hence, 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. Number analyzed = participants evaluable for specified categories.

Sub-RPE compartment measures reflect the disease burden between the RPE and Bruch's membrane. The sub-RPE central 1 mm mean thickness refers to the average thickness of the retina within a 1-mm diameter circular area centered around the fovea (the central part of the retina).

Outcome measures

Measure	Danicopan 100 mg BID n=72 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=65 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=72 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=70 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 and Week 104 in Sub-RPE Central 1 mm Subfield Mean Thickness in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 52	-2.61 µm Standard Deviation 5.838	-2.89 µm Standard Deviation 4.863	-2.87 µm Standard Deviation 5.842	-0.04 µm Standard Deviation 12.832	-2.97 µm Standard Deviation 5.403	-2.13 µm Standard Deviation 6.814	5.19 µm Standard Deviation 20.081	—	—	—
Change From Baseline to Week 52 and Week 104 in Sub-RPE Central 1 mm Subfield Mean Thickness in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 104	-3.24 µm Standard Deviation 11.423	-4.33 µm Standard Deviation 7.450	-5.26 µm Standard Deviation 9.398	—	-3.72 µm Standard Deviation 7.208	-6.38 µm Standard Deviation 9.288	-4.72 µm Standard Deviation 9.648	—	—	—
Change From Baseline to Week 52 and Week 104 in Sub-RPE Central 1 mm Subfield Mean Thickness in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 52	-0.84 µm Standard Deviation 6.699	-1.50 µm Standard Deviation 3.274	-2.42 µm Standard Deviation 6.345	-2.33 µm Standard Deviation 8.500	-1.13 µm Standard Deviation 11.960	-0.59 µm Standard Deviation 3.463	-5.00 µm Standard Deviation 6.941	—	—	—
Change From Baseline to Week 52 and Week 104 in Sub-RPE Central 1 mm Subfield Mean Thickness in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 104	-3.58 µm Standard Deviation 9.171	-4.18 µm Standard Deviation 6.176	-6.73 µm Standard Deviation 9.984	—	-10.56 µm Standard Deviation 11.610	-3.90 µm Standard Deviation 5.368	-9.36 µm Standard Deviation 12.776	—	—	—
Change From Baseline to Week 52 and Week 104 in Sub-RPE Central 1 mm Subfield Mean Thickness in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 52	-3.23 µm Standard Deviation 9.340	-3.95 µm Standard Deviation 5.893	-5.05 µm Standard Deviation 9.529	-2.04 µm Standard Deviation 14.876	-3.83 µm Standard Deviation 12.208	-2.60 µm Standard Deviation 7.605	0.40 µm Standard Deviation 21.689	—	—	—
Change From Baseline to Week 52 and Week 104 in Sub-RPE Central 1 mm Subfield Mean Thickness in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 104	-5.74 µm Standard Deviation 14.485	-7.04 µm Standard Deviation 9.644	-11.72 µm Standard Deviation 16.323	—	-12.52 µm Standard Deviation 16.342	-9.50 µm Standard Deviation 12.294	-14.08 µm Standard Deviation 21.741	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in FAS (randomized participants who received at least 1 dose \[full/partial\] of study drug grouped by randomized treatment) with both baseline and post-baseline (Week 52 and Week 104) visit sub-RPE central macular 2 mm subfield mean thickness data. As prespecified, data were collected and reported for participants. Hence, 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. Number analyzed = participants evaluable for specified categories.

Sub-RPE compartment measures reflect the disease burden between the RPE and Bruch's membrane. The sub-RPE central macular 2 mm subfield thickness refers to the thickness of the retina within a 2-mm radius in the central part of the macula.

Outcome measures

Measure	Danicopan 100 mg BID n=72 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=65 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=72 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=70 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 and Week 104 in Sub-RPE Central Macular 2 mm Subfield Mean Thickness in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 52	-2.75 µm Standard Deviation 4.229	-3.34 µm Standard Deviation 3.314	-3.02 µm Standard Deviation 4.064	-1.88 µm Standard Deviation 5.550	-3.36 µm Standard Deviation 4.148	-2.06 µm Standard Deviation 3.834	-0.15 µm Standard Deviation 7.701	—	—	—
Change From Baseline to Week 52 and Week 104 in Sub-RPE Central Macular 2 mm Subfield Mean Thickness in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 104	-5.80 µm Standard Deviation 9.514	-5.35 µm Standard Deviation 4.290	-6.22 µm Standard Deviation 3.954	—	-3.78 µm Standard Deviation 7.190	-4.32 µm Standard Deviation 2.743	-5.16 µm Standard Deviation 4.527	—	—	—
Change From Baseline to Week 52 and Week 104 in Sub-RPE Central Macular 2 mm Subfield Mean Thickness in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 52	-1.66 µm Standard Deviation 4.750	-3.07 µm Standard Deviation 3.575	-2.93 µm Standard Deviation 3.552	-3.12 µm Standard Deviation 5.733	-2.79 µm Standard Deviation 7.131	-1.24 µm Standard Deviation 3.434	-5.06 µm Standard Deviation 5.370	—	—	—
Change From Baseline to Week 52 and Week 104 in Sub-RPE Central Macular 2 mm Subfield Mean Thickness in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 104	-4.42 µm Standard Deviation 9.773	-9.15 µm Standard Deviation 13.049	-6.33 µm Standard Deviation 5.931	—	-9.90 µm Standard Deviation 10.970	-5.08 µm Standard Deviation 2.898	-12.30 µm Standard Deviation 10.238	—	—	—
Change From Baseline to Week 52 and Week 104 in Sub-RPE Central Macular 2 mm Subfield Mean Thickness in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 52	-4.06 µm Standard Deviation 6.749	-5.51 µm Standard Deviation 5.298	-5.67 µm Standard Deviation 5.790	-4.50 µm Standard Deviation 7.649	-5.66 µm Standard Deviation 7.552	-3.03 µm Standard Deviation 4.963	-4.77 µm Standard Deviation 9.770	—	—	—
Change From Baseline to Week 52 and Week 104 in Sub-RPE Central Macular 2 mm Subfield Mean Thickness in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 104	-8.61 µm Standard Deviation 12.280	-11.28 µm Standard Deviation 12.963	-12.22 µm Standard Deviation 8.602	—	-12.03 µm Standard Deviation 16.671	-8.38 µm Standard Deviation 5.509	-17.46 µm Standard Deviation 11.297	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment group) with both baseline and post-baseline (Week 52 and Week 104) visit panmacular sub-RPE volume data. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. Number analyzed = participants evaluable for specified categories.

Sub-RPE compartment measures reflect the disease burden between the RPE and Bruch's membrane. The panmacular sub-RPE volume refers to the total volume of fluid or space located underneath the RPE across the entire macula (the central part of the retina).

Outcome measures

Measure	Danicopan 100 mg BID n=72 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=65 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=72 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=70 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 and Week 104 in Panmacular Sub-RPE Volume in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 52	-0.04 mm^3 Standard Deviation 0.052	-0.04 mm^3 Standard Deviation 0.050	-0.05 mm^3 Standard Deviation 0.059	-0.04 mm^3 Standard Deviation 0.066	-0.06 mm^3 Standard Deviation 0.079	-0.03 mm^3 Standard Deviation 0.064	-0.03 mm^3 Standard Deviation 0.051	—	—	—
Change From Baseline to Week 52 and Week 104 in Panmacular Sub-RPE Volume in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 104	-0.08 mm^3 Standard Deviation 0.076	-0.07 mm^3 Standard Deviation 0.085	-0.09 mm^3 Standard Deviation 0.065	—	-0.05 mm^3 Standard Deviation 0.094	-0.10 mm^3 Standard Deviation 0.063	-0.06 mm^3 Standard Deviation 0.091	—	—	—
Change From Baseline to Week 52 and Week 104 in Panmacular Sub-RPE Volume in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 52	-0.04 mm^3 Standard Deviation 0.074	-0.04 mm^3 Standard Deviation 0.048	-0.04 mm^3 Standard Deviation 0.054	-0.04 mm^3 Standard Deviation 0.068	-0.05 mm^3 Standard Deviation 0.082	-0.02 mm^3 Standard Deviation 0.053	-0.06 mm^3 Standard Deviation 0.062	—	—	—
Change From Baseline to Week 52 and Week 104 in Panmacular Sub-RPE Volume in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 104	-0.08 mm^3 Standard Deviation 0.084	-0.09 mm^3 Standard Deviation 0.098	-0.08 mm^3 Standard Deviation 0.085	—	-0.11 mm^3 Standard Deviation 0.114	-0.05 mm^3 Standard Deviation 0.050	-0.17 mm^3 Standard Deviation 0.123	—	—	—
Change From Baseline to Week 52 and Week 104 in Panmacular Sub-RPE Volume in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 52	-0.07 mm^3 Standard Deviation 0.102	-0.06 mm^3 Standard Deviation 0.073	-0.08 mm^3 Standard Deviation 0.088	-0.08 mm^3 Standard Deviation 0.111	-0.09 mm^3 Standard Deviation 0.142	-0.05 mm^3 Standard Deviation 0.089	-0.08 mm^3 Standard Deviation 0.093	—	—	—
Change From Baseline to Week 52 and Week 104 in Panmacular Sub-RPE Volume in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 104	-0.14 mm^3 Standard Deviation 0.127	-0.12 mm^3 Standard Deviation 0.160	-0.17 mm^3 Standard Deviation 0.128	—	-0.14 mm^3 Standard Deviation 0.196	-0.14 mm^3 Standard Deviation 0.085	-0.24 mm^3 Standard Deviation 0.074	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment group) with both baseline and post-baseline (Week 52 and Week 104) visit macular total RPE attenuation data. As prespecified, data were collected and reported for participants. Therefore, 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. Number analyzed = participants evaluable for specified categories.

Macular total RPE attenuation refers to the degree of thinning or loss of the RPE in the macula, the central part of the retina responsible for sharp, detailed vision. This was measured as a percentage of the macular area affected.

Outcome measures

Measure	Danicopan 100 mg BID n=72 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=65 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=72 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=70 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 and Week 104 in Percent Macular Total RPE Attenuation in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 52	10.36 percentage of macular area Standard Deviation 6.652	8.58 percentage of macular area Standard Deviation 5.429	11.42 percentage of macular area Standard Deviation 6.976	10.62 percentage of macular area Standard Deviation 7.048	10.09 percentage of macular area Standard Deviation 6.376	9.06 percentage of macular area Standard Deviation 6.227	12.73 percentage of macular area Standard Deviation 8.186	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Macular Total RPE Attenuation in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 52	6.11 percentage of macular area Standard Deviation 3.874	5.11 percentage of macular area Standard Deviation 2.706	6.38 percentage of macular area Standard Deviation 3.718	5.48 percentage of macular area Standard Deviation 3.413	5.47 percentage of macular area Standard Deviation 3.043	5.00 percentage of macular area Standard Deviation 3.328	6.00 percentage of macular area Standard Deviation 3.916	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Macular Total RPE Attenuation in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 104	10.66 percentage of macular area Standard Deviation 6.579	9.18 percentage of macular area Standard Deviation 5.951	11.64 percentage of macular area Standard Deviation 4.956	—	7.86 percentage of macular area Standard Deviation 4.673	12.68 percentage of macular area Standard Deviation 6.330	11.77 percentage of macular area Standard Deviation 5.205	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Macular Total RPE Attenuation in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 52	5.23 percentage of macular area Standard Deviation 3.594	5.00 percentage of macular area Standard Deviation 3.549	5.59 percentage of macular area Standard Deviation 4.513	6.18 percentage of macular area Standard Deviation 4.043	5.55 percentage of macular area Standard Deviation 3.474	5.18 percentage of macular area Standard Deviation 3.740	7.66 percentage of macular area Standard Deviation 4.545	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Macular Total RPE Attenuation in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 104	10.96 percentage of macular area Standard Deviation 6.159	8.50 percentage of macular area Standard Deviation 6.472	11.49 percentage of macular area Standard Deviation 8.582	—	10.38 percentage of macular area Standard Deviation 7.719	11.82 percentage of macular area Standard Deviation 6.691	16.12 percentage of macular area Standard Deviation 4.807	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Macular Total RPE Attenuation in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 104	18.20 percentage of macular area Standard Deviation 12.155	14.14 percentage of macular area Standard Deviation 11.759	22.52 percentage of macular area Standard Deviation 12.076	—	16.51 percentage of macular area Standard Deviation 12.246	22.14 percentage of macular area Standard Deviation 10.270	27.89 percentage of macular area Standard Deviation 8.760	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment) with both baseline and post-baseline (Week 52 and Week 104) visit central 1 mm subfield total RPE attenuation data. As prespecified, data were collected and reported for participants. Hence, 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. Number analyzed = participants evaluable for specified categories.

The percentage of total attenuation of the RPE in the central 1 mm subfield is reported.

Outcome measures

Measure	Danicopan 100 mg BID n=72 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=65 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=72 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=70 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 and Week 104 in Percent Central 1 mm Subfield Total RPE Attenuation in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 52	10.27 percentage of total RPE attenuation Standard Deviation 13.204	8.60 percentage of total RPE attenuation Standard Deviation 11.277	9.60 percentage of total RPE attenuation Standard Deviation 13.794	8.16 percentage of total RPE attenuation Standard Deviation 12.335	9.85 percentage of total RPE attenuation Standard Deviation 13.381	9.02 percentage of total RPE attenuation Standard Deviation 13.346	5.48 percentage of total RPE attenuation Standard Deviation 9.989	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central 1 mm Subfield Total RPE Attenuation in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 104	15.56 percentage of total RPE attenuation Standard Deviation 18.923	14.77 percentage of total RPE attenuation Standard Deviation 12.017	19.42 percentage of total RPE attenuation Standard Deviation 18.209	—	13.89 percentage of total RPE attenuation Standard Deviation 12.330	28.62 percentage of total RPE attenuation Standard Deviation 27.097	15.79 percentage of total RPE attenuation Standard Deviation 29.801	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central 1 mm Subfield Total RPE Attenuation in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 52	7.48 percentage of total RPE attenuation Standard Deviation 12.846	5.91 percentage of total RPE attenuation Standard Deviation 10.333	8.67 percentage of total RPE attenuation Standard Deviation 11.815	9.69 percentage of total RPE attenuation Standard Deviation 15.031	7.33 percentage of total RPE attenuation Standard Deviation 10.670	6.46 percentage of total RPE attenuation Standard Deviation 7.800	14.81 percentage of total RPE attenuation Standard Deviation 21.405	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central 1 mm Subfield Total RPE Attenuation in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 104	15.43 percentage of total RPE attenuation Standard Deviation 13.245	9.84 percentage of total RPE attenuation Standard Deviation 13.900	20.71 percentage of total RPE attenuation Standard Deviation 18.542	—	21.88 percentage of total RPE attenuation Standard Deviation 20.194	22.45 percentage of total RPE attenuation Standard Deviation 22.899	23.19 percentage of total RPE attenuation Standard Deviation 37.563	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central 1 mm Subfield Total RPE Attenuation in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 52	16.29 percentage of total RPE attenuation Standard Deviation 21.116	12.79 percentage of total RPE attenuation Standard Deviation 16.127	17.43 percentage of total RPE attenuation Standard Deviation 19.549	16.23 percentage of total RPE attenuation Standard Deviation 21.394	15.85 percentage of total RPE attenuation Standard Deviation 19.996	14.08 percentage of total RPE attenuation Standard Deviation 18.363	18.76 percentage of total RPE attenuation Standard Deviation 25.857	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central 1 mm Subfield Total RPE Attenuation in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 104	26.10 percentage of total RPE attenuation Standard Deviation 21.267	21.13 percentage of total RPE attenuation Standard Deviation 18.674	39.11 percentage of total RPE attenuation Standard Deviation 27.628	—	32.12 percentage of total RPE attenuation Standard Deviation 28.775	46.58 percentage of total RPE attenuation Standard Deviation 43.859	38.98 percentage of total RPE attenuation Standard Deviation 66.640	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in FAS (all randomized participants who received at least 1 dose \[full/partial\] of study drug grouped by randomized treatment) with both baseline and postbaseline (Week 52 and Week 104) visit central macular 2 mm subfield total RPE attenuation data. As prespecified, data were collected and reported for participants. Hence, 'Ns' reported below= number of participants analyzed regardless of which eye was evaluated. Number analyzed= participants evaluable for specified categories.

The percentage of total attenuation of the RPE in the central macular 2 mm subfield is reported.

Outcome measures

Measure	Danicopan 100 mg BID n=72 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=65 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=72 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=70 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 and Week 104 in Percent Central Macular 2 mm Subfield Total RPE Attenuation in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 52	11.07 percentage of total RPE attenuation Standard Deviation 8.790	10.86 percentage of total RPE attenuation Standard Deviation 7.042	11.21 percentage of total RPE attenuation Standard Deviation 8.539	10.18 percentage of total RPE attenuation Standard Deviation 9.265	12.20 percentage of total RPE attenuation Standard Deviation 9.228	8.89 percentage of total RPE attenuation Standard Deviation 8.759	9.41 percentage of total RPE attenuation Standard Deviation 9.869	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central Macular 2 mm Subfield Total RPE Attenuation in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Study Eye: Change at Week 104	22.11 percentage of total RPE attenuation Standard Deviation 18.777	20.14 percentage of total RPE attenuation Standard Deviation 11.243	22.35 percentage of total RPE attenuation Standard Deviation 9.980	—	14.87 percentage of total RPE attenuation Standard Deviation 10.962	20.32 percentage of total RPE attenuation Standard Deviation 5.212	13.47 percentage of total RPE attenuation Standard Deviation 11.872	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central Macular 2 mm Subfield Total RPE Attenuation in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 52	8.84 percentage of total RPE attenuation Standard Deviation 9.019	8.99 percentage of total RPE attenuation Standard Deviation 11.116	10.56 percentage of total RPE attenuation Standard Deviation 9.026	11.50 percentage of total RPE attenuation Standard Deviation 8.889	11.30 percentage of total RPE attenuation Standard Deviation 7.522	8.36 percentage of total RPE attenuation Standard Deviation 7.234	14.38 percentage of total RPE attenuation Standard Deviation 10.698	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central Macular 2 mm Subfield Total RPE Attenuation in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Fellow Eye: Change at Week 104	17.54 percentage of total RPE attenuation Standard Deviation 13.638	12.04 percentage of total RPE attenuation Standard Deviation 10.432	20.96 percentage of total RPE attenuation Standard Deviation 12.092	—	22.81 percentage of total RPE attenuation Standard Deviation 19.741	26.77 percentage of total RPE attenuation Standard Deviation 6.514	26.85 percentage of total RPE attenuation Standard Deviation 20.134	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central Macular 2 mm Subfield Total RPE Attenuation in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 52	18.22 percentage of total RPE attenuation Standard Deviation 13.985	17.22 percentage of total RPE attenuation Standard Deviation 13.792	20.75 percentage of total RPE attenuation Standard Deviation 13.888	19.74 percentage of total RPE attenuation Standard Deviation 14.674	21.58 percentage of total RPE attenuation Standard Deviation 14.796	15.43 percentage of total RPE attenuation Standard Deviation 11.951	22.13 percentage of total RPE attenuation Standard Deviation 16.571	—	—	—
Change From Baseline to Week 52 and Week 104 in Percent Central Macular 2 mm Subfield Total RPE Attenuation in the Study Eye, Fellow Eye and Both Eyes Combined as Measured by SD-OCT Both Eyes Combined: Change at Week 104	33.38 percentage of total RPE attenuation Standard Deviation 19.938	27.94 percentage of total RPE attenuation Standard Deviation 19.154	42.14 percentage of total RPE attenuation Standard Deviation 18.854	—	33.88 percentage of total RPE attenuation Standard Deviation 27.642	41.73 percentage of total RPE attenuation Standard Deviation 15.668	40.32 percentage of total RPE attenuation Standard Deviation 28.798	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in the FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment group) with both baseline and post-baseline (Week 52 and Week 104) visit BCVA score data. As prespecified, data were collected and reported for participants. Therefore, 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. Number analyzed = participants evaluable at specified timepoints.

ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).

Outcome measures

Measure	Danicopan 100 mg BID n=73 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=68 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=75 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=70 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 and Week 104 in Monocular Best-corrected Visual Acuity (BCVA) Scores in the Study Eye as Assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart Change at Week 104	-1.3 letters Standard Deviation 4.71	-2.2 letters Standard Deviation 12.30	-10.2 letters Standard Deviation 16.37	—	-2.7 letters Standard Deviation 6.62	-3.2 letters Standard Deviation 5.54	-5.4 letters Standard Deviation 6.39	—	—	—
Change From Baseline to Week 52 and Week 104 in Monocular Best-corrected Visual Acuity (BCVA) Scores in the Study Eye as Assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart Change at Week 52	-2.2 letters Standard Deviation 8.56	-2.0 letters Standard Deviation 9.39	-3.5 letters Standard Deviation 11.35	-1.8 letters Standard Deviation 5.60	-2.4 letters Standard Deviation 5.74	-2.0 letters Standard Deviation 4.39	-0.9 letters Standard Deviation 6.58	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in the FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment group) with both baseline and post-baseline (Week 52 and Week 104) visit LLVA score data. As prespecified, data were collected and reported for participants. Therefore, 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. Number analyzed = participants evaluable at specified timepoints.

LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. LLVA was reported as number of letters read correctly by the participant using the ETDRS Scale (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Change from baseline: a negative score indicates decline in LLVA.

Outcome measures

Measure	Danicopan 100 mg BID n=74 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=67 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=72 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=70 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=22 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 and Week 104 in Monocular Low Luminance Visual Acuity (LLVA) Scores in the Study Eye as Assessed by the ETDRS Chart Change at Week 52	-6.3 letters Standard Deviation 11.61	-4.6 letters Standard Deviation 11.77	-4.0 letters Standard Deviation 11.23	-4.8 letters Standard Deviation 15.96	-7.7 letters Standard Deviation 13.43	-1.2 letters Standard Deviation 17.90	-5.5 letters Standard Deviation 16.71	—	—	—
Change From Baseline to Week 52 and Week 104 in Monocular Low Luminance Visual Acuity (LLVA) Scores in the Study Eye as Assessed by the ETDRS Chart Change at Week 104	-10.3 letters Standard Deviation 14.27	-9.9 letters Standard Deviation 14.15	-8.9 letters Standard Deviation 10.39	—	-8.0 letters Standard Deviation 10.37	-3.9 letters Standard Deviation 20.88	-11.8 letters Standard Deviation 15.86	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in the FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment group) with both baseline and post-baseline (Week 52 and Week 104) visit LLD score data. As prespecified, data were collected and reported for participants. Therefore, 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. Number analyzed = participants evaluable at specified timepoints.

LLD score was calculated as the difference between BCVA and LLVA (BCVA-LLVA) scores. BCVA and LLVA were reported as the number of letters read correctly by the participant using the ETDRS Scale (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision. LLD is a measure of visual acuity impairment in low-light conditions. A higher LLD score indicates a greater difference between vision in bright and dim light, suggesting a more significant loss of visual function in low-luminance settings.

Outcome measures

Measure	Danicopan 100 mg BID n=74 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=67 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=71 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=70 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=22 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 and Week 104 in Low Luminance Deficit (LLD) (BCVA-LLVA) Score in the Study Eye Change at Week 52	4.3 letters Standard Deviation 13.30	2.6 letters Standard Deviation 13.68	0.3 letters Standard Deviation 15.67	2.9 letters Standard Deviation 15.18	5.3 letters Standard Deviation 12.56	-0.8 letters Standard Deviation 17.15	4.5 letters Standard Deviation 15.84	—	—	—
Change From Baseline to Week 52 and Week 104 in Low Luminance Deficit (LLD) (BCVA-LLVA) Score in the Study Eye Change at Week 104	5.6 letters Standard Deviation 17.11	6.3 letters Standard Deviation 15.22	0.5 letters Standard Deviation 19.93	—	4.4 letters Standard Deviation 13.83	-2.7 letters Standard Deviation 24.00	9.3 letters Standard Deviation 15.91	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in the FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment group) with both baseline and post-baseline (Week 52 and Week 104) visit reading speed data. As prespecified, data were collected and reported for participants. Therefore, 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. Number analyzed = participants evaluable at specified timepoints.

MNRead acuity cards were continuous-text reading-acuity cards suitable for measuring the reading acuity and reading speed of normal and low-vision participants. The MNRead acuity cards consisted of single, simple sentences with equal numbers of characters. A stopwatch was used to record time to a tenth of a second. Sentences that could not be read or were not attempted due to vision should be recorded as 0 for time and 10 for errors. The Radner Reading Cards were suitable for measuring reading speed, reading visual acuity, and critical print size. The reading test was stopped when the reading time was longer than 20 seconds or when the participant was making severe errors. A negative change from baseline indicates a decrease in the monocular reading speed; disease worsening.

Outcome measures

Measure	Danicopan 100 mg BID n=67 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=62 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=58 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=56 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=20 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=15 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=20 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 And Week 104 in Monocular Reading Speeds in the Study Eye as Assessed by Minnesota Low Vision Reading Test (MNRead) Acuity Charts or Radner Reading Charts Change at Week 52	-137.36 words per minute (wpm) Standard Deviation 1016.889	-19.80 words per minute (wpm) Standard Deviation 42.134	-13.47 words per minute (wpm) Standard Deviation 77.927	-14.55 words per minute (wpm) Standard Deviation 81.313	16.22 words per minute (wpm) Standard Deviation 104.097	-41.54 words per minute (wpm) Standard Deviation 53.752	-30.46 words per minute (wpm) Standard Deviation 61.042	—	—	—
Change From Baseline to Week 52 And Week 104 in Monocular Reading Speeds in the Study Eye as Assessed by Minnesota Low Vision Reading Test (MNRead) Acuity Charts or Radner Reading Charts Change at Week 104	16.04 words per minute (wpm) Standard Deviation 142.422	-23.70 words per minute (wpm) Standard Deviation 57.745	-29.01 words per minute (wpm) Standard Deviation 65.896	—	-59.41 words per minute (wpm) Standard Deviation 43.156	30.18 words per minute (wpm) Standard Deviation 144.094	-47.13 words per minute (wpm) Standard Deviation 71.218	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 and Week 104

Population: All participants in the FAS (all randomized participants who received at least 1 dose \[full or partial\] of study drug grouped by randomized treatment group) with both baseline and post-baseline (Week 52 and Week 104) visit NEI VFQ-25 scores data. As prespecified, data were collected and reported for participants. Therefore, 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. Number analyzed = participants evaluable at specified timepoints.

The NEI VFQ-25 instrument measures dimensions of self-reported vision-targeted health status of individuals with chronic eye conditions. The NEI VFQ-25 consists of 11 vision related domains: global vision rating, difficulty with near vision activities, difficulty with distance vision activities, limitations in social function related to vision, role limitations, dependency on others due to vision, mental health symptoms due to vision, driving difficulties, limitations with peripheral- and color-vision, and ocular pain. The NEI VFQ-25 also includes a single item measuring general health. A composite score averages the vision related domains and ranges from 0 (worse) to 100 (best). A higher score represents better functioning. A negative change from baseline indicates a decrease in the visual functioning; disease worsening.

Outcome measures

Measure	Danicopan 100 mg BID n=73 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=67 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=75 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=70 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline to Week 52 and Week 104 in National Eye Institute Visual Function Questionnaire (NEI VFQ-25) Composite Scores Change at Week 52	-0.425 units on a scale Standard Deviation 9.6019	-5.816 units on a scale Standard Deviation 11.9162	-4.456 units on a scale Standard Deviation 9.4963	-1.578 units on a scale Standard Deviation 11.0757	-1.058 units on a scale Standard Deviation 9.1822	-4.856 units on a scale Standard Deviation 11.4575	1.156 units on a scale Standard Deviation 12.0823	—	—	—
Change From Baseline to Week 52 and Week 104 in National Eye Institute Visual Function Questionnaire (NEI VFQ-25) Composite Scores Change at Week 104	-7.676 units on a scale Standard Deviation 16.3251	-8.478 units on a scale Standard Deviation 13.5192	-7.454 units on a scale Standard Deviation 14.2207	—	-0.332 units on a scale Standard Deviation 13.3618	0.535 units on a scale Standard Deviation 10.7239	-9.944 units on a scale Standard Deviation 13.4043	—	—	—

SECONDARY outcome

Timeframe: Day 1 and Week 52

Population: Pharmacokinetic (PK) Analysis Set included all participants who received at least 1 dose (full or partial) of study drug and had at least 1 measurable concentration value. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed' = participants evaluable at specified timepoint.

All values below the limit of quantification (<0.1 nanograms [ng]/milliliter [mL]) were set to 0 for calculation of summary statistics.

Outcome measures

Measure	Danicopan 100 mg BID n=91 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=87 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=89 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Plasma Concentration of Danicopan Day 1: Predose	0.4 ng/mL Standard Deviation 3.41	0 ng/mL Standard Deviation 0	0.2 ng/mL Standard Deviation 1.67	—	—	—	—	—	—	—
Plasma Concentration of Danicopan Day 1: 2 Hour Postdose	289.6 ng/mL Standard Deviation 202.88	507.5 ng/mL Standard Deviation 279.71	844.5 ng/mL Standard Deviation 563.54	—	—	—	—	—	—	—
Plasma Concentration of Danicopan Week 52: Predose	62.5 ng/mL Standard Deviation 40.64	127.7 ng/mL Standard Deviation 100.78	88.1 ng/mL Standard Deviation 138.95	—	—	—	—	—	—	—
Plasma Concentration of Danicopan Week 52: 2 Hour Postdose	381.6 ng/mL Standard Deviation 219.22	704.4 ng/mL Standard Deviation 336.37	919.5 ng/mL Standard Deviation 709.94	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Week 52 (pre-dose, 2 hours post-dose)

Population: Pharmacodynamic (PD) Analysis Set included all participants who received at least 1 dose (full or partial) of study drug and had at least 1 measurable PD value. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed' = participants evaluable at specified timepoint.

Serum AP functional activity was measured by the Wieslab functional immunoassay method.

Outcome measures

Measure	Danicopan 100 mg BID n=67 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=68 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=70 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=68 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline in Ex Vivo Serum Alternative Pathway (AP) Activity Change at Week 52: Predose	-5.9 percentage of activity Standard Deviation 17.49	-21.3 percentage of activity Standard Deviation 29.90	-8.2 percentage of activity Standard Deviation 24.48	2.7 percentage of activity Standard Deviation 17.12	—	—	—	—	—	—
Change From Baseline in Ex Vivo Serum Alternative Pathway (AP) Activity Change at Week 52: 2 Hour Postdose	-58.5 percentage of activity Standard Deviation 27.85	-75.3 percentage of activity Standard Deviation 23.17	-74.8 percentage of activity Standard Deviation 28.82	-23.1 percentage of activity Standard Deviation 42.12	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline, Week 52 (pre-dose)

Population: PD Analysis Set included all participants who received at least 1 dose (full or partial) of study drug and had at least 1 measurable PD value. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.

Outcome measures

Measure	Danicopan 100 mg BID n=66 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=65 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=72 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=70 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Change From Baseline in Plasma Bb Fragment of Complement Factor B (Bb) Concentration	-0.3 µg/mL Standard Deviation 0.77	-0.7 µg/mL Standard Deviation 0.94	-0.2 µg/mL Standard Deviation 0.55	-0.1 µg/mL Standard Deviation 0.55	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 through Week 108

Population: Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.

An adverse event (AE) was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), or an important medical event or reaction. A TEAE was defined as any AE that started during or after the first dose of study intervention. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Outcome measures

Measure	Danicopan 100 mg BID n=93 Participants Participants received danicopan 100 mg BID during the 104-week Masked Treatment Period.	Danicopan 200 mg BID n=91 Participants Participants received danicopan 200 mg BID during the 104-week Masked Treatment Period.	Danicopan 400 mg QD n=91 Participants Participants received danicopan 400 mg QD during the 104-week Masked Treatment Period.	Placebo n=90 Participants Participants received matching placebo and were re-randomized to one of the active treatment groups at Week 52.	Placebo - Danicopan 200 mg BID n=73 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Placebo - Danicopan 400 mg QD n=67 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Placebo - Danicopan 400 mg QD n=73 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID n=24 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD n=23 Participants Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Events Leading To Discontinuation of Study Drug Throughout the Study SAEs	14 Participants	19 Participants	16 Participants	15 Participants	8 Participants	10 Participants	8 Participants	6 Participants	4 Participants	4 Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Events Leading To Discontinuation of Study Drug Throughout the Study Any TEAEs	79 Participants	83 Participants	76 Participants	71 Participants	51 Participants	37 Participants	46 Participants	19 Participants	12 Participants	17 Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Events Leading To Discontinuation of Study Drug Throughout the Study Events Leading To Discontinuation of Study Drug	11 Participants	15 Participants	9 Participants	11 Participants	1 Participants	2 Participants	4 Participants	0 Participants	2 Participants	4 Participants

Adverse Events

Primary Evaluation Period: Danicopan 100 mg BID

Serious events: 14 serious events

Other events: 44 other events

Deaths: 0 deaths

Primary Evaluation Period: Danicopan 200 mg BID

Serious events: 19 serious events

Other events: 42 other events

Deaths: 1 deaths

Primary Evaluation Period: Danicopan 400 mg QD

Serious events: 16 serious events

Other events: 33 other events

Deaths: 0 deaths

Primary Evaluation Period: Placebo

Serious events: 15 serious events

Other events: 33 other events

Deaths: 3 deaths

Secondary Evaluation Period: Danicopan 100 mg BID

Serious events: 8 serious events

Other events: 22 other events

Deaths: 1 deaths

Secondary Evaluation Period: Danicopan 200 mg BID

Serious events: 10 serious events

Other events: 14 other events

Deaths: 1 deaths

Secondary Evaluation Period: Danicopan 400 mg QD

Serious events: 8 serious events

Other events: 16 other events

Deaths: 1 deaths

Secondary Evaluation Period: Placebo - Danicopan 100 mg BID

Serious events: 6 serious events

Other events: 12 other events

Deaths: 1 deaths

Secondary Evaluation Period: Placebo - Danicopan 200 mg BID

Serious events: 4 serious events

Other events: 7 other events

Deaths: 0 deaths

Secondary Evaluation Period: Placebo - Danicopan 400 mg QD

Serious events: 4 serious events

Other events: 8 other events

Deaths: 0 deaths

Serious adverse events

Measure	Primary Evaluation Period: Danicopan 100 mg BID n=93 participants at risk Participants received danicopan 100 mg BID during the 52-week Primary Evaluation Period.	Primary Evaluation Period: Danicopan 200 mg BID n=91 participants at risk Participants received danicopan 200 mg BID during the 52-week Primary Evaluation Period.	Primary Evaluation Period: Danicopan 400 mg QD n=91 participants at risk Participants received danicopan 400 mg QD during the 52-week Primary Evaluation Period.	Primary Evaluation Period: Placebo n=90 participants at risk Participants received matching placebo during the 52-week Primary Evaluation Period.	Secondary Evaluation Period: Danicopan 100 mg BID n=73 participants at risk Participants received danicopan 100 mg BID during the 52-week Secondary Evaluation Period.	Secondary Evaluation Period: Danicopan 200 mg BID n=67 participants at risk Participants received danicopan 200 mg BID during the 52-week Secondary Evaluation Period.	Secondary Evaluation Period: Danicopan 400 mg QD n=73 participants at risk Participants received danicopan 400 mg QD during the 52-week Secondary Evaluation Period.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID n=24 participants at risk Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID n=23 participants at risk Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD n=23 participants at risk Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Eye disorders Macular hole	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Eye disorders Visual acuity reduced	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Blood and lymphatic system disorders Iron deficiency anaemia	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Cardiac disorders Acute myocardial infarction	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Cardiac disorders Atrial fibrillation	1.1% 1/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Cardiac disorders Cardiac arrest	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.5% 1/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.2% 1/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Cardiac disorders Coronary artery disease	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Cardiac disorders Myocardial infarction	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Cardiac disorders Tachycardia	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Ear and labyrinth disorders Deafness unilateral	1.1% 1/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Gastrointestinal disorders Obstructive pancreatitis	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Gastrointestinal disorders Pancreatitis	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Gastrointestinal disorders Rectal haemorrhage	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
General disorders Induration	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
General disorders Malaise	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Hepatobiliary disorders Drug-induced liver injury	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Hepatobiliary disorders Cholelithiasis	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Infections and infestations COVID-19	1.1% 1/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	2.2% 2/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Infections and infestations Bacterial sepsis	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Infections and infestations COVID-19 pneumonia	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Infections and infestations Cellulitis	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Infections and infestations Groin abscess	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Infections and infestations Herpes zoster	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Infections and infestations Influenza	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Infections and infestations Pneumonia	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	2.7% 2/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.2% 1/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Infections and infestations Respiratory syncytial virus infection	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Infections and infestations Respiratory tract infection bacterial	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Infections and infestations Sepsis	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Infections and infestations Superinfection bacterial	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Infections and infestations Urinary tract infection	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.1% 3/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Injury, poisoning and procedural complications Skin laceration	1.1% 1/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Injury, poisoning and procedural complications Femoral neck fracture	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.2% 1/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Injury, poisoning and procedural complications Forearm fracture	1.1% 1/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Injury, poisoning and procedural complications Ligament sprain	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Injury, poisoning and procedural complications Lower limb fracture	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Injury, poisoning and procedural complications Tibia fracture	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Investigations Hepatic enzyme increased	2.2% 2/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	2.2% 2/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Metabolism and nutrition disorders Hypervolaemia	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Musculoskeletal and connective tissue disorders Arthralgia	1.1% 1/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Musculoskeletal and connective tissue disorders Intervertebral disc disorder	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Musculoskeletal and connective tissue disorders Intervertebral disc protrusion	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	3.0% 2/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Invasive ductal breast carcinoma	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma of colon	1.1% 1/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Benign salivary gland neoplasm	1.1% 1/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Intraductal proliferative breast lesion	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung neoplasm malignant	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant melanoma stage IV	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to spine	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Myelodysplastic syndrome	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostatic adenoma	1.1% 1/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Transitional cell carcinoma	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Nervous system disorders Cerebrovascular accident	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Nervous system disorders Hypoxic-ischaemic encephalopathy	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Nervous system disorders Transient ischaemic attack	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Psychiatric disorders Disorientation	1.1% 1/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Renal and urinary disorders Nephrolithiasis	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Renal and urinary disorders Renal failure	1.1% 1/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	1.1% 1/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Respiratory, thoracic and mediastinal disorders Organising pneumonia	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	1.1% 1/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Vascular disorders Hypertension	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Vascular disorders Haematoma	1.1% 1/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Vascular disorders Hypertensive emergency	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Eye disorders Neovascular age-related macular degeneration	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.2% 1/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Infections and infestations Endophthalmitis	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.3% 1/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Cardiac disorders Angina unstable	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.5% 1/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Cardiac disorders Arrhythmia	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.5% 1/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Cardiac disorders Cardiac failure	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.3% 1/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Cardiac disorders Cardiac failure congestive	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.5% 1/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Cardiac disorders Sinus node dysfunction	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.3% 1/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Cardiac disorders Ventricular tachycardia	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Ear and labyrinth disorders Vertigo	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Gastrointestinal disorders Constipation	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.2% 1/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.3% 1/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Gastrointestinal disorders Large intestine polyp	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.5% 1/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Gastrointestinal disorders Pancreatitis acute	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.3% 1/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Gastrointestinal disorders Proctitis	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.2% 1/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
General disorders Asthenia	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Hepatobiliary disorders Cholecystitis acute	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.5% 1/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Hepatobiliary disorders Hepatic cirrhosis	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.3% 1/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Hepatobiliary disorders Hydrocholecystis	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.3% 1/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Infections and infestations Streptococcal bacteraemia	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Infections and infestations Diabetic foot infection	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.3% 1/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Infections and infestations Gastrointestinal infection	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Injury, poisoning and procedural complications Fall	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	3.0% 2/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Injury, poisoning and procedural complications Ankle fracture	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Injury, poisoning and procedural complications Pelvic fracture	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Injury, poisoning and procedural complications Rib fracture	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Injury, poisoning and procedural complications Toxicity to various agents	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Injury, poisoning and procedural complications Traumatic arthrosis	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.3% 1/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Injury, poisoning and procedural complications Upper limb fracture	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Investigations Electrocardiogram QT prolonged	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.5% 1/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Investigations Haemoglobin decreased	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Metabolism and nutrition disorders Hypoglycaemia	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.5% 1/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Metabolism and nutrition disorders Hypernatraemia	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.2% 1/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.5% 1/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Brain neoplasm malignant	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.5% 1/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon cancer	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.3% 1/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neuroendocrine carcinoma	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Nervous system disorders Syncope	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.5% 1/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Nervous system disorders Dizziness	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.5% 1/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Product Issues Device breakage	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.5% 1/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Psychiatric disorders Mental status changes	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Renal and urinary disorders Renal colic	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.

Other adverse events

Measure	Primary Evaluation Period: Danicopan 100 mg BID n=93 participants at risk Participants received danicopan 100 mg BID during the 52-week Primary Evaluation Period.	Primary Evaluation Period: Danicopan 200 mg BID n=91 participants at risk Participants received danicopan 200 mg BID during the 52-week Primary Evaluation Period.	Primary Evaluation Period: Danicopan 400 mg QD n=91 participants at risk Participants received danicopan 400 mg QD during the 52-week Primary Evaluation Period.	Primary Evaluation Period: Placebo n=90 participants at risk Participants received matching placebo during the 52-week Primary Evaluation Period.	Secondary Evaluation Period: Danicopan 100 mg BID n=73 participants at risk Participants received danicopan 100 mg BID during the 52-week Secondary Evaluation Period.	Secondary Evaluation Period: Danicopan 200 mg BID n=67 participants at risk Participants received danicopan 200 mg BID during the 52-week Secondary Evaluation Period.	Secondary Evaluation Period: Danicopan 400 mg QD n=73 participants at risk Participants received danicopan 400 mg QD during the 52-week Secondary Evaluation Period.	Secondary Evaluation Period: Placebo - Danicopan 100 mg BID n=24 participants at risk Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 100 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 200 mg BID n=23 participants at risk Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 200 mg BID for the remainder of the study.	Secondary Evaluation Period: Placebo - Danicopan 400 mg QD n=23 participants at risk Participants who received placebo during the primary evaluation period (up to Week 52), were re-randomized to receive danicopan 400 mg QD for the remainder of the study.
Investigations Gamma-glutamyltransferase increased	9.7% 9/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	7.7% 7/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	5.5% 5/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	3.3% 3/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.5% 1/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	12.5% 3/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	8.7% 2/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	13.0% 3/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Investigations C-reactive protein increased	1.1% 1/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	3.3% 3/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	7.7% 7/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	6.7% 6/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.1% 3/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	3.0% 2/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	2.7% 2/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	12.5% 3/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.3% 1/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Investigations Hepatic enzyme increased	5.4% 5/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	6.6% 6/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.4% 4/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.2% 1/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	8.7% 2/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	8.7% 2/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Investigations Blood alkaline phosphatase increased	4.3% 4/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.4% 4/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	5.5% 5/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.5% 1/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.2% 1/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.3% 1/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Investigations Alanine aminotransferase increased	5.4% 5/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	5.5% 5/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	2.2% 2/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.5% 1/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.2% 1/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.3% 1/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.3% 1/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Eye disorders Cataract	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	3.3% 3/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	3.3% 3/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.5% 3/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	5.5% 4/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.2% 1/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Nervous system disorders Headache	5.4% 5/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.4% 4/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	6.6% 6/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	2.2% 2/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.5% 1/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.2% 1/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.3% 1/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Vascular disorders Hypertension	6.5% 6/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.4% 4/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	3.3% 3/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	3.3% 3/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	6.0% 4/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	2.7% 2/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Cardiac disorders Atrial fibrillation	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	3.3% 3/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.2% 1/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	8.7% 2/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
General disorders Pyrexia	0.00% 0/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	2.2% 2/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	5.5% 4/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.2% 1/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Eye disorders Neovascular age-related macular degeneration	5.4% 5/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	5.5% 5/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	5.5% 5/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	3.3% 3/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.1% 3/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	3.0% 2/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.2% 1/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.3% 1/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.3% 1/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Gastrointestinal disorders Nausea	5.4% 5/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	3.3% 3/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.4% 4/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	3.3% 3/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.1% 3/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.5% 1/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.3% 1/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Gastrointestinal disorders Abdominal pain upper	5.4% 5/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.5% 1/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Infections and infestations COVID-19	5.4% 5/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	7.7% 7/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	9.9% 9/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	8.9% 8/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	2.7% 2/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.5% 3/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	8.2% 6/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.2% 1/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	8.7% 2/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	8.7% 2/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Infections and infestations Urinary tract infection	6.5% 6/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	6.6% 6/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	9.9% 9/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	5.6% 5/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	11.0% 8/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	3.0% 2/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	5.5% 4/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	12.5% 3/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.3% 1/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Infections and infestations Nasopharyngitis	9.7% 9/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	5.5% 5/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	3.3% 3/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	8.9% 8/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	5.5% 4/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.5% 3/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	4.1% 3/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	8.3% 2/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	8.7% 2/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Injury, poisoning and procedural complications Fall	2.2% 2/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	2.2% 2/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	3.3% 3/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	8.2% 6/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.4% 1/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.
Injury, poisoning and procedural complications Contusion	1.1% 1/93 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	3.3% 3/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	2.2% 2/91 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.1% 1/90 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	2.7% 2/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	1.5% 1/67 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/73 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	8.3% 2/24 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.	0.00% 0/23 • Day 1 through Week 108 Safety Set included all participants who received at least 1 dose (full or partial) of study drug grouped by treatment actually received. 'Deaths' as the 'reason for study discontinuation' have been reported in the participant flow section and 'all deaths' have been reported in the 'All-cause mortality' section. As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated.

Additional Information

Alexion Pharmaceuticals Inc.

Alexion Pharmaceuticals Inc.

Phone: +1 855-752-2356

Email: clinicaltrials@alexion.com

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place